

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E23/22 - Hormones 2

Deadline: 26.07.2022

| | | |
|--|--|--|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of the participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U _{AV} = expanded uncertainty of the assigned value (k = 2) | |

| Test | [unit] | Comparability | | | | | | N _{eva} | N _{suc} | S _{rel} | |
|------------------------------------|----------|---------------|------|--------|------------------|------------------|---|------------------|------------------|------------------|-----------------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | | | | U _{AV} |
| (393) C-peptide | | | | | 11 | | | | 10 | 8 | 80% |
| Samples and groups | [pmol/L] | | | | | | | | | | |
| Sample A | | 380 | 91 | 24 | 11 | | | | 10 | 8 | 80% |
| Other | | | | | 11 | 1 | | | 10 | | |
| | | | | | | | 3x 4/1, 1x 4/29, 4x 4/60, 3x 4/179 | | | | |
| Sample B | | 150 | 49 | 33 | 11 | | | | 10 | 9 | 90% |
| Other | | | | | 11 | 0 | | | 10 | | |
| | | | | | | | 3x 4/1, 1x 4/29, 4x 4/60, 3x 4/179 | | | | |
| (193) Ferritin | | | | | 14 | | | | 14 | 14 | 100% |
| Samples and groups | [µg/L] | | | | | | | | | | |
| Sample A | | 313 | 71 | 23 | 14 | | | | 14 | 14 | 100% |
| Other | | | | | 14 | 0 | | | 14 | | |
| | | | | | | | 3x 4/1, 1x 4/12, 4x 4/60, 2x 4/162, 3x 4/179, 1x 6/60 | | | | |
| Sample B | | 34,9 | 7,6 | 22 | 14 | | | | 14 | 14 | 100% |
| Other | | | | | 14 | 0 | | | 14 | | |
| | | | | | | | 3x 4/1, 1x 4/12, 4x 4/60, 2x 4/162, 3x 4/179, 1x 6/60 | | | | |
| (321) FSH | | | | | 12 | | | | 12 | 12 | 100% |
| Samples and groups | [U/L] | | | | | | | | | | |
| Sample A | | 26,9 | 1,3 | 4,8 | 12 | | | | 12 | 12 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 26,7 | 1,0 | 3,8 | 5 | 0 | CVPG | 27,0,16 | 15% | 22,9 | 31,1 |
| (60) Roche | | | | | | | | | | | |
| Other | | | | | 7 | 0 | | | 7 | | |
| | | | | | | | 1x 3/25, 3x 4/1, 2x 4/12, 1x 4/162 | | | | |
| Sample B | | 15,3 | 1,5 | 10 | 12 | | | | 12 | 12 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 14,7 | 0,24 | 1,7 | 5 | 0 | CVPG | 14,9 | 0,080 | 15% | 12,6 |
| (60) Roche | | | | | | | | | | | |
| Other | | | | | 7 | 0 | | | 7 | | |
| | | | | | | | 1x 3/25, 3x 4/1, 2x 4/12, 1x 4/162 | | | | |
| (328) hGH | | | | | 7 | | | | 7 | 7 | 100% |
| Samples and groups | [mU/L] | | | | | | | | | | |
| Sample A | | 25,5 | 2,6 | 10 | 7 | | | | 7 | 7 | 100% |
| Other | | | | | 7 | 0 | | | 7 | | |
| | | | | | | | 2x 4/12, 4x 4/29, 1x 4/60 | | | | |
| Sample B | | 2,74 | 0,79 | 29 | 7 | | | | 7 | 7 | 100% |
| Other | | | | | 7 | 0 | | | 7 | | |
| | | | | | | | 2x 4/12, 4x 4/29, 1x 4/60 | | | | |
| (329) IGF-1 | | | | | 6 | | | | 6 | 6 | 100% |
| Samples and groups | [µg/L] | | | | | | | | | | |
| Sample A | | 343 | 19 | 5,6 | 6 | | | | 6 | 6 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 344 | 18 | 5,2 | 5 | 0 | CVPG | 345 | 8,2 | 22% | 269 |
| (29) Siemens (Immulite) | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | 1 | | |
| | | | | | | | 1x 4/60 | | | | |
| Sample B | | 150 | 9,6 | 6,4 | 6 | | | | 6 | 6 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 153 | 4,4 | 2,9 | 5 | 0 | CVPG | 149 | 3,4 | 22% | 116 |
| (29) Siemens (Immulite) | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | 1 | | |
| | | | | | | | 1x 4/60 | | | | |
| (392) IGF-BP3 | | | | | 2 | | | | 2 | 2 | 100% |
| Samples and groups | [µg/L] | | | | | | | | | | |
| Sample A | | 3660 | 440 | 12 | 2 | | | | 2 | 2 | 100% |
| Other | | | | | 2 | 0 | | | 2 | | |
| | | | | | | | 1x 4/29, 1x 4/60 | | | | |
| Sample B | | 3580 | 420 | 12 | 2 | | | | 2 | 2 | 100% |
| Other | | | | | 2 | 0 | | | 2 | | |
| | | | | | | | 1x 4/29, 1x 4/60 | | | | |
| (325) Insulin | | | | | 8 | | | | 8 | 8 | 100% |
| Samples and groups | [mU/L] | | | | | | | | | | |
| Sample A | | 24,6 | 5,9 | 24 | 8 | | | | 8 | 8 | 100% |
| Other | | | | | 8 | 0 | | | 8 | | |
| | | | | | | | 2x 4/1, 3x 4/60, 3x 4/179 | | | | |
| Sample B | | 17,5 | 3,2 | 18 | 8 | | | | 8 | 8 | 100% |
| Other | | | | | 8 | 0 | | | 8 | | |
| | | | | | | | 2x 4/1, 3x 4/60, 3x 4/179 | | | | |
| (326) Folate | | | | | 14 | | | | 14 | 14 | 100% |
| Samples and groups | [nmol/L] | | | | | | | | | | |
| Sample A | | 43,5 | 3,1 | 7,1 | 14 | | | | 14 | 14 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 41,4 | 2,1 | 5,0 | 5 | 0 | CVPG | 40,5 | 0,48 | 27% | 29,5 |
| (60) Roche | | | | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E23/22 - Hormones 2

Deadline: 26.07.2022

| Test | [unit] | | | | | | Comparability | | | | | | | |
|--|----------|-------|-------|--------|------------------|------------------|---|-----------------|------------------|-------|-------|------------------|------------------|------------------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} |
| (326) Folate | | | | | 14 | | | | | | | 14 | 14 | 100% |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | |
| Sample A | | 43,5 | 3,1 | 7,1 | 14 | | | | | | | 14 | 14 | 100% |
| Other | | | | | 9 | 0 | | | | | | 9 | | |
| | | | | | | | 4x 4/1, 1x 4/12, 1x 4/162, 3x 4/179 | | | | | | | |
| Sample B | | 57,5 | 16 | 28 | 14 | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 68,1 | 34 | 49 | 5 | 1 | CVPG | 45,4 | 0,0054 | 27% | 33,1 | 57,7 | 0 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 9 | 0 | | | | | | 0 | | |
| | | | | | | | 4x 4/1, 1x 4/12, 1x 4/162, 3x 4/179 | | | | | | | |
| (320) LH | | | | | 12 | | | | | | | 11 | 10 | 91% |
| Samples and groups | [U/L] | | | | | | | | | | | | | |
| Sample A | | 79,0 | 11 | 13 | 12 | | | | | | | 11 | 10 | 91% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 86,3 | 1,9 | 2,2 | 5 | 0 | CVPG | 86,2 | 0,56 | 15% | 73,2 | 99,2 | 5 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 7 | 0 | | | | | | 6 | | |
| | | | | | | | 1x 3/25, 3x 4/1, 2x 4/12, 1x 4/162 | | | | | | | |
| Sample B | | 8,10 | 2,0 | 25 | 12 | | | | | | | 11 | 10 | 91% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 9,81 | 0,18 | 1,8 | 5 | 0 | CVPG | 9,76 | 0,063 | 15% | 8,29 | 11,3 | 5 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 7 | 0 | | | | | | 6 | | |
| | | | | | | | 1x 3/25, 3x 4/1, 2x 4/12, 1x 4/162 | | | | | | | |
| (405) Parathyroid hormone (PTH) | | | | | 12 | | | | | | | 12 | 12 | 100% |
| Samples and groups | [pmol/L] | | | | | | | | | | | | | |
| Sample A | | 15,9 | 2,3 | 15 | 12 | | | | | | | 12 | 12 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 15,2 | 1,6 | 10 | 10 | 0 | CVPG | 15,6 | 0,14 | 23% | 12 | 19,2 | 10 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | |
| | | | | | | | 1x 4/1, 1x 4/12 | | | | | | | |
| Sample B | | 0,437 | 0,074 | 17 | 12 | | | | | | | 12 | 12 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 0,450 | 0,07 | 16 | 10 | 0 | CVPG | 0,565 | 0,015 ± 0,276 | 0,289 | 0,841 | 10 | | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | |
| | | | | | | | 1x 4/1, 1x 4/12 | | | | | | | |
| (322) Prolactin | | | | | 12 | | | | | | | 11 | 11 | 100% |
| Samples and groups | [mU/L] | | | | | | | | | | | | | |
| Sample A | | 537 | 79 | 15 | 12 | | | | | | | 11 | 11 | 100% |
| Other | | | | | 12 | 0 | | | | | | 11 | | |
| | | | | | | | 1x 3/25, 2x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 3x 4/179 | | | | | | | |
| Sample B | | 188 | 32 | 17 | 12 | | | | | | | 11 | 11 | 100% |
| Other | | | | | 12 | 0 | | | | | | 11 | | |
| | | | | | | | 1x 3/25, 2x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 3x 4/179 | | | | | | | |
| (390) Renin | | | | | 5 | | | | | | | 5 | 4 | 80% |
| Samples and groups | [ng/L] | | | | | | | | | | | | | |
| Sample A | | 45,8 | 5,1 | 11 | 5 | | | | | | | 5 | 4 | 80% |
| Other | | | | | 5 | 0 | | | | | | 5 | | |
| | | | | | | | 1x 1/185, 4x 4/164 | | | | | | | |
| Sample B | | 58,6 | 4,0 | 6,9 | 5 | | | | | | | 5 | 4 | 80% |
| Other | | | | | 5 | 0 | | | | | | 5 | | |
| | | | | | | | 1x 1/185, 4x 4/164 | | | | | | | |
| (394) SHBG | | | | | 8 | | | | | | | 8 | 8 | 100% |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | |
| Sample A | | 33,8 | 3,1 | 9,2 | 8 | | | | | | | 8 | 8 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 33,7 | 1,6 | 4,7 | 5 | 0 | CVPG | 32,3 | 0,26 | 20% | 25,8 | 38,8 | 5 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | 3 | | |
| | | | | | | | 1x 4/1, 1x 4/12, 1x 4/29 | | | | | | | |
| Sample B | | 62,2 | 7,6 | 12 | 8 | | | | | | | 8 | 8 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 62,5 | 2,9 | 4,6 | 5 | 0 | CVPG | 61,3 | 0,50 | 20% | 49 | 73,6 | 5 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | 3 | | |
| | | | | | | | 1x 4/1, 1x 4/12, 1x 4/29 | | | | | | | |
| (327) Vitamin B12 | | | | | 14 | | | | | | | 14 | 12 | 86% |
| Samples and groups | [pmol/L] | | | | | | | | | | | | | |
| Sample A | | 276 | 40 | 14 | 14 | | | | | | | 14 | 12 | 86% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 278 | 26 | 9,2 | 5 | 0 | CVPG | 287 | 2,5 | 20% | 229 | 345 | 5 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 9 | 0 | | | | | | 9 | | |
| | | | | | | | 4x 4/1, 1x 4/12, 1x 4/162, 3x 4/179 | | | | | | | |
| Sample B | | 969 | 130 | 14 | 14 | | | | | | | 14 | 14 | 100% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 900 | 56 | 6,2 | 5 | 0 | CVPG | 919 | 5,2 | 20% | 735 | 1110 | 5 | |
| (60) Roche | | | | | | | | | | | | | | |
| Other | | | | | 9 | 0 | | | | | | 9 | | |
| | | | | | | | 4x 4/1, 1x 4/12, 1x 4/162, 3x 4/179 | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E23/22 - Hormones 2

Deadline: 26.07.2022

| Test | [unit] | RoM | SD | CV [%] | N _{tot} | N _{out} | Comparability | | | | | | | |
|-----------------------------------|----------|------|-----|-----------|------------------|------------------|---------------------------|-----------------|------------------|----|----|------------------|------------------|---------------------|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} |
| (319) Vitamin B12 (active) | | | | | 5 | | | | | | | 4 | 4 | 100% |
| ----- Samples and groups ----- | [pmol/L] | | | | | | | | | | | | | |
| Sample A | | 82,8 | 7,6 | 9,2 | 5 | | | | | | | 4 | 4 | 100% |
| Other | | | | | 5 | 0 | | | | | | 4 | | |
| | | | | | | | 2x 4/1, 2x 4/60, 1x 4/179 | | | | | | | |
| Sample B | | 201 | 82 | 41 | 5 | | | | | | | 0 | | |
| Other | | | | | 5 | 0 | | | | | | 0 | | |
| | | | | | | | 2x 4/1, 2x 4/60, 1x 4/179 | | | | | | | |
| st_kn_p | | | | | | | End of report | | | | | | | Printed: 30.07.2022 |